ORIC

ORIC is a pre-revenue, clinical-stage oncology company — five straight years of widening losses (-$78.7M in FY2021 to -$129M in FY2025) and a -$692M accumulated deficit reflect that reality, not a deteriorating business. The right lens is runway × catalyst quality, and on both fronts the picture is constructive. FY2025 saw stockholders' equity jump +58.1% to $384M and total assets rise +49.2% to $409M against just $24.5M of liabilities (L/E of 0.06x), evidence of a sizable equity raise — confirmed by the +41.3% YoY jump in shares outstanding to 100M. Cash & equivalents at $45.7M look thin in isolation, but with $288M in current assets vs. $20.4M current liabilities, ORIC almost certainly holds the bulk of its capital in short-term investments. Against -$111M operating cash burn (essentially flat YoY), that implies roughly 2–2.5 years of runway — enough to reach key inflection points without an immediate dilution gun to the head.

The MD&A is where the thesis lives. Rinzimetostat's November 2025 Phase 1b dose-exploration data in mCRPC is the standout: 55% PSA50 (40% confirmed), 20% PSA90 (all confirmed), 76% of patients with >50% ctDNA reduction and 59% achieving ctDNA clearance — across both apalutamide and darolutamide combos, with only one Grade 3 TRAE and no Grade 4/5 AEs attributed to study drugs. Management has selected RP2Ds and committed to initiating a global Phase 3 registrational trial in mCRPC in 1H 2026, with dose-optimization data in Q1 2026. Enozertinib adds a second shot on goal in EGFR exon 20 / atypical mutation NSCLC, with December 2025 ESMO Asia data showing CNS activity in 98 patients. Two de-risked assets with branded-pharma collaboration partners (J&J, Bayer) is more than most $1B-cap biotechs have.